Hummingbird Bioscience, a Singapore-based company focused on antibody discovery, pharmacology, and clinical development, has raised US$125 million in its latest round of funding.

More funding details

Lead investor: Novo HoldingsOther investors: Frazier Healthcare Partners, Octagon Capital, EDBI, Amgen Ventures, Droia Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group, and Altrium Capital ManagementReturning investors: SK, Heritas Capital, and Mirae Asset Venture CapitalStage: Series C